Drug Type Peptide Conjugate Radionuclide, Therapeutic radiopharmaceuticals |
Synonyms- |
Target |
Action inhibitors |
Mechanism PSMA inhibitors(Prostate-specific membrane antigen inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic castration-resistant prostate cancer | Phase 2 | Australia | 29 Sep 2022 |
Phase 1/2 | Metastatic castration-resistant prostate cancer PSMA-positive disease | 30 | Terbium-161[161Tb]Tb-PSMA-I&T | ccuvujkpwf(brjczavqog) = uugoggxdxn gbcrbzdrrw (crebwpcolj, 51 - 85) View more | Positive | 30 May 2025 |